Cadazolid

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Cadazolid is an oxazolidinone-type antibiotic, with activity against gram-positive bacteria, including Clostridium difficile.

Cadazolid, also known ACT-179811, is a novel fluoroquinolone-oxazolidinone antibiotic and a protein synthesis inhibitor. Cadazolid may be potentially useful for the treatment of Clostridium difficile infection. Cadazolid exhibits potent in vitro activity against Clostridium difficile, including the epidemic BI/NAP1/027 strain. Clostridium difficile infection (CDI), the main cause of nosocomial infectious diarrhea, results from the growth of toxin-producing C. difficile in the colon following disruption of the normal enteric microbiota, usually as a consequence of antibiotic therapy.

ACT-179811;Cadazolid.

Others

Other Targets

Others

——

——

1025097-10-2

585.19

C29H29F2N3O8

98%

DMSO : ≥ 150 mg/mL 256.17 mM

c1c(c(cc2c1n(cc(c2=O)C(=O)O)C1CC1)F)N1CCC(CC1)(COc1c(cc(cc1)N1C[C@@H](OC1=O)CO)F)O

1-Cyclopropyl-6-fluoro-7-[4-({2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenoxy}methyl)-4-hydroxypiperidin-1-yl]-4-oxo-1,4-dihydroquinolin-3-carboxylic acid

(-20℃)

With Ice Pack

≥ 2 years